atherosclerosis

A new model suggests that a protein involved in the generation of high-density lipoprotein (HDL) works differently than previously thought.

An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.

Over 10 years, multiple healthy behaviors did not slow the progression of arterial stiffness, a risk factor for coronary artery disease, hypertension, stroke, atrial fibrillation and heart failure.

Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.

Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.

A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.